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Abstract   
 
Omeprazole (OME) is a proton pump inhibitor (PPI) with 58% bioavailability after a 
single oral dose. It is subject to marked inter-individual variations and significant drug-
drug interactions. The authors developed a simple and rapid method based on liquid 
chromatography in tandem with mass spectrometry (LC/MS-MS) with solid phase 
extraction (SPE) and isotope-labelled internal standard (IS) to monitor plasma levels of 
OME in pharmacokinetics and drug-drug interaction studies. OME and its IS (OME-
D3) were eluted with the Zorbax Extend C-18 rapid resolution column (4.6 mm x 50 
mm, 3.5 μm) at 25ºC, under isocratic conditions through a mobile phase consisting of 1 
mM ammonium acetate, pH 8.5 (55%), and acetonitrile (ACN, 45%). The flow rate was 
0.8 mL/min, and the chromatogram run time was 1.2 min. OME was detected and 
quantified by LC-MS/MS with positive electrospray ionization (ESI), which operates in 
multiple-reaction monitoring (MRM) mode. The method was linear in the range of 1.5-
2000 ng/mL for OME. The validation assays for accuracy and precision, matrix effect, 
extraction recovery, and stability of the samples for OME did not deviate more than 
20% for the lower limit of quantification (LLOQ) and no more than 15% for other 
quality controls (QCs). These findings are consistent with the requirements of 
regulatory agencies.  
 
 
Keywords: Omeprazole; liquid chromatography in tandem with mass spectrometry; 
solid phase extraction; proton pump inhibitor; peptic ulcer. 
 
 
Abbreviations used:  
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ACN: Acetonitrile 
CAL: Calibration standard 
Cmax: Maximum plasma concentration  
AUC: Area under curve  
CV: Coefficient of variation  
EDTA: Ethylenediaminetetraacetic acid 
EIC: Extraction ion chromatogram  
EMA: European Medicines Agency  
ESI: Electrospray ionization  
FDA: Food and Drug Administration  
HPLC: High-performance liquid chromatography  
IS: Internal standard  
LC-MS/MS: Liquid chromatography in tandem with mass spectrometry  
LLE: Liquid-liquid extraction 
LLOQ: Lower limit of quantification  
MeOH: Methanol  
MRM: Multiple-reaction monitoring  
OME: Omeprazole 
PPI: Proton pump inhibitor 
PPT: Protein precipitation 
QC: Quality control  
R
2
: Correlation coefficient 
RT: Retention time 
SD: Standard deviation  
4 
SPE: Solid phase extraction 
Tmax: Time of occurrence of Cmax 
T1/2: Half-life 
TIC: Total ion chromatogram  
UV: Ultraviolet  
5 
 
1. Introduction 
 
The prodrug omeprazole (OME) is a substituted benzimidazole (6-methoxy-2-[(4-
methoxy-3,5- dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole) that acts as a 
specific PPI by reducing the amount of gastric acid produced by parietal cells. OME 
was the first PPI used to treat stomach ulcers, gastroesophageal reflux disease, 
Zollinger-Ellison syndrome, and infection by Helicobacter pylori 
1-3
. The bioavailability 
after a single oral dose of 40 mg OME is approximately 58% owing to first-pass liver 
metabolism 
1-3
  
Drug-drug interactions with OME result from increased gastric pH or inhibition of the 
metabolism of some drugs 
4, 5
. For instance, phenytoin, warfarin, diazepam, and 
citalopram decreased clearance 
6-9
; digoxin increased and clopidogrel decreased 
absorption 
10, 11
. Therefore, the extensive pharmacokinetic variability of OME and its 
interactions with other drugs—few are clinically significant—mean that there are 
situations in which OME must be monitored. Dosage would therefore have to be 
tailored to individual patient requirements, and pharmacokinetic studies would be 
necessary to clarify drug-drug interactions, particularly in the case of polymedicated 
elderly patients or those receiving drugs with a narrow therapeutic index. 
To date, plasma OME levels have been analyzed using high-performance liquid 
chromatography (HPLC) with coulometric detection 
12
 and ultraviolet detection (UV) 
13-
19
. However, the lower limit of quantification (LLOQ) in this technique is higher or the 
run time longer than in methods based on liquid chromatography in tandem with 
mass spectrometry (LC-MS/MS) and electrospray ionization (ESI) 
20-25
. Although 
LC-MS/MS improves sensitivity and selectivity, ESI is hampered by ion suppression or 
6 
by enhancement from the sample matrix 
26
 and interference from metabolites 
27
. Solid 
phase extraction (SPE) and application of an isotope-labeled internal standard (IS) 
reduced the matrix effect. Matuszewski 
28
 showed that the use of stable isotope-labelled 
IS eliminated the relative matrix effect due to similarities between physical-chemical 
properties, thus reducing variability during sample preparation and ionization. 
However, most LC-MS/MS methods with ESI are based on protein precipitation (PPT) 
22
 or liquid-liquid extraction (LLE) 
21, 23, 24
, or non-isotopic labelled IS instead of SPE 
and stable isotope-labelled IS. Although SPE has been carried out using HPLC with UV 
detection 
14
 and LC-MS/MS 
25, 29
, performance times were longer, evaporation and 
reconstitution steps were necessary, and neither technique was based on isotope-labelled 
IS. Dodgen and coworkers 
20
 used LC-MS/MS with automated online SPE and column 
switching; however, this technology is available in very few laboratories and is difficult 
to adapt to routine therapeutic drug monitoring. 
 
Therefore, the aim of the present study was to develop a simple, sensitive, and 
reproducible LC-MS/MS method based on SPE and isotope-labelled IS (OME-D3) to 
monitor plasma levels of OME in pharmacokinetics and drug-drug interaction studies 
using enhanced speed of analysis and optimized chromatographic conditions.   
 
 
2. Materials and Methods 
 
2.1 Chemicals and reagents 
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All chemicals were analytical or LC-MS grade. OME (6-methoxy-2-[[(4-methoxy-3,5-
dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole) and OME-D3 (6-(methoxy-
d3)-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole) were 
supplied by Toronto Research Chemicals Inc. (North York, Canada) and acetic acid by 
Panreac Quimica (Madrid, Spain). Methanol (MeOH), acetonitrile (ACN) and 
ammonium acetate were purchased from LAB-SCAN Analytical Science (SYMTA, 
Madrid, Spain). The water for preparing the mobile phase was obtained using a Milli-Q 
system (Millipore-Ibérica, Madrid, Spain). Blank human plasma samples were from 2 
sources: the Blood Donation Unit of Hospital Universitario de la Princesa, Madrid, 
Spain and the Transfusion Center of the Autonomous Community of Madrid. 
 
 
2.2 Stock solutions, calibration standards (CALs), and quality controls (QCs) 
 
Two separate stock solutions of OME, one for CALs and another for QCs were 
prepared by dissolving an accurately weighed quantity in MeOH to obtain a 
concentration of 1 mg/mL. Both stock solutions were diluted independently to obtain 
several secondary and working solutions for the preparation of CALs and QCs. The IS 
(OME-D3) stock solution was prepared by dissolving an exact amount in MeOH to 
obtain a concentration of 1 mg/mL and diluted 40 times to give a working solution of 25 
μg/mL. CALs were prepared by independent dilution, in which a specific volume of 
secondary CAL solutions (0.15 g/mL, 1 mg/mL, 5 g/mL, 20 g/mL, 50 g/mL, 100 
g/mL, 150 g/mL, and 200 g/mL) was added to blank plasma to obtain 
concentrations of 1.5, 10, 50, 200, 500, 1000, 1500, and 2000 ng/mL, respectively. A 
calibration curve (1.5 to 2000 ng/mL) was thus generated according to the 
8 
recommendations of the United States Food and Drug Administration (FDA) 
30
 and the 
European Medicines Agency (EMA) 
31
 for bioanalytical method validation. QC samples 
were also made by independent dilution, in which a specific volume of QC secondary 
solutions (0.15 g/mL, 0.45 g/mL, 900 g/mL, and 1600 g/mL, respectively) was 
added to blank plasma to obtain concentrations of 1.5 ng/mL (LLOQ), 4.5 (QCLow), 900 
ng/mL (QCMedium), and 1600 ng/mL (QCHigh), respectively. A drug-free blank plasma 
sample and drug-free zero plasma sample (processed with IS) were included. All CAL 
and QC solutions were stored at –80°C until analysis to avoid more than 3 cycles of 
freezing. Storage was no longer than 2 months. 
 
 
2.3 Chromatographic conditions 
 
The HPLC system consisted of a 1200 Series separation module (Agilent Technologies, 
Madrid, Spain) combined with Agilent MassHunter Workstation Data Acquisition 
software for programming samples and controlling chromatographic conditions. 
Separations were carried out at 25ºC in a Zorbax Extend C18 Rapid Resolution column 
(4.6 mm x 50 mm [particle size 3.5 µm] Agilent Technologies, Madrid, Spain). The 
mobile phase consisted of a combination of ammonium acetate 1 mM in water (pH = 
8.5, solution A) and ACN (solution B). It is important to maintain this pH during 
recording, because OME is very sensitive to acidic pH. The chromatographic run was 
performed under isocratic conditions at a flow rate of 0.8 mL/min with 55% solution A 
and 45% solution B. The elution time of each sample was 0.889 min for OME and 
0.884 min for OME D3. The total run time was 1.2 min, and a re-equilibration time was 
not required owing to the isocratic conditions used. At the end of every day, the column 
9 
was washed by increasing the percentage of ACN to 100% at a 0.8-mL/min flow rate 
for 20 min and then returning to the initial conditions within 5 min. Washing was then 
continued for a further 10 min.  
 
 
2.4 Mass spectrometry 
 
The mass spectrometry detection system consisted of an Agilent Technologies 6410 
triple quadrupole mass spectrometer with ESI in positive ion mode. Mass spectrometry 
was performed in multiple-reaction monitoring (MRM) mode. Desolvation gas (N2) and 
flow were set at 310°C and 8.5 L/min, respectively. Thus, the acetic acid of the mobile 
phase was easily volatilized at this temperature. The nebulizer pressure was 40 psi, 
which assured good nebulization efficiency for the chromatographic conditions; the 
capillary voltage was 4 kV. The mass spectrometry collision gas was high-purity N2 (> 
99.9995). The fragmentor voltage was 75 V and dwell time 200 ms for all compounds. 
The collision energy was set at 5 eV for OME (quantifier ion) and OME-D3, and at 15 
eV for OME (qualifier ion). After separation with HPLC, the peak area corresponding 
to the transition m/z 346.2 → 198.1 for OME (quantifier ion) was measured relative to 
that of the transition m/z 349.2 → 198 for its IS (OME-D3). For identification of OME, 
the m/z 346.2 → 151.1 reaction for the qualifier ion was also monitored to add 
specificity (Supplementary Table 1 and Fig. 1A-B). The integration peak area of the 
MRM transitions of each analyte was calculated using MassHunter Workstation 
Quantitative Analysis software (Agilent Technologies, Madrid, Spain). 
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2.5 Sample preparation 
 
Samples were prepared by SPE using Nexus Versaplate Bond Elute C18 and 30 mg of 
polymeric sorbent (Agilent Technologies, Madrid, Spain) with a vacuum pressure of 
about 3-5 mmHg. The sample was applied after pre-conditioning of the cartridges with 
1000 L MeOH followed by 1000 L Milli-Q water. This procedure was carried out by 
spiking 200 L of plasma with 10 L of IS (25 g/mL) and 790 L of ammonium 
acetate 1 mM (pH 8.5) for one sample, although the IS was calculated for more samples 
and pre-mixed with ammonium acetate for the general procedure. Next, a washing step 
was performed with 1000 L of 95% ammonium acetate 1 mM (pH 8.5) in 5% MeOH. 
Elution was performed with 1000 L of 90% MeOH and 10% ACN plus 1% 
ammonium acetate 1 mM in water (pH 8.5), which was collected on a 96-well (1 mL) 
plate. After extraction, samples were transferred to vials or they were directly read from 
the collection plate. Only 1 L of eluate was directly injected into the LC-MS/MS. The 
whole sample preparation procedure was carried out at pH 8.5 to ensure the stability of 
OME, which degrades rapidly under acidic solutions 
32
. 
 
 
2.6  Assay validation procedures 
 
The method was validated in order to demonstrate the reliability of OME in plasma, its 
biological matrix. Accordingly, the authors followed the recommendations published 
online by the FDA 
30
 and the EMA 
31
.  
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2.6.1 Calibration curve and LLOQ 
 
Quantitative analysis of OME in plasma was performed using OME D3 as the IS. Eight 
calibration standards—1.5, 10, 50, 200, 500, 1000, 1500, 2000 ng/mL—were used for 
validation. A weighted least-square linear regression model was used to calculate the 
equation relating the ratio of the area of OME to the area of IS and the concentration of 
OME in the calibration standards. The inverse of the concentration (1/X
2
) was used as a 
weighting factor. Six standard curves were analyzed. The standard curve was chosen to 
cover the range of clinically relevant concentrations expected in most patients. To 
validate the curve, at least 6 of 8 calibration standards should be less than 15% of the 
coefficient of variation (CV). For each point of the calibration curve, the error of 
accuracy and CV should be less than 15% for all calibration standards, except for the 
LLOQ, which was less than 20%. The LLOQ response of the analyte should be at least 
5 times higher than the blank response. 
 
 
2.6.2 Precision and accuracy 
 
The precision, repeatability, and accuracy of the assay (ie, the closeness of the 
determined value to the true value) are critical factors when measuring reproducibility. 
“The authors assessed the precision and accuracy of the method by analyzing 
replicate QC samples of 1.5 ng/mL (LLOQ), 10 ng/mL (QCLow), 900 ng/mL 
(QCMedium), and 1600 ng/mL (QCHigh) of OME. The intra-day precision and 
accuracy were evaluated by analyzing 5 samples of each QC on a single day. The 
inter-day variation was evaluated by injecting a further 5 samples of each QC 
12 
sample (LLOQ, QCLow, QCMedium, and QCHigh) on 3 consecutive days. In all the 
samples the pre-treatment procedure was performed before the injection”. 
Precision is defined as a coefficient of variation (%). Accuracy was measured as the 
percentage difference between the theoretical and the measured value according to the 
following equation: 
 
 
Accuracy (%) = (concentrationmeasured – concentrationtheoretical)  
                          (concentrationtheoretical) x 100% 
 
To verify precision and accuracy, error must be less than 15% for all samples except the 
LLOQ (<20%). 
 
 
2.6.3 Selectivity  
 
The selectivity of the method was examined by analyzing 6 different lots from human 
blank plasma, with the IS (zero plasma) or without the IS. Each blank or zero sample 
was tested for interference. The method is considered selective when the response is less 
than 5 times the LLOQ for OME and less than 20 times for the IS.  
 
 
2.6.4 Extraction recovery and matrix effect 
 
13 
Recovery is measured as the ratio of the compound concentrations in plasma following 
SPE to the same concentration dissolved directly in elution solution. Three repetitions 
of the QCs for OME (4.5 ng/mL [QCLow], 900 ng/mL [QCMedium], and 1600 ng/mL 
[QCHigh] ng/mL) were analyzed in 3 different lots of human plasma. To be adequate, 
recovery of the analyte did not need to be 100%, but the extent of recovery of QC 
samples had to be precise, reliable, and reproducible.  
The matrix effect of plasma was investigated by addition of a known concentration of 
analyte with its IS to a human blank plasma sample that had undergone SPE. The 
response was compared with the addition of the same amount of analyte and IS to the 
final elution solution. This time, 6 repetitions per concentration were analyzed in 6 
different lots of human plasma at 4.5 ng/mL (QCLow) and 1600 ng/mL (QCHigh) for 
OME. To validate the matrix effect, the coefficient of variation (CV) could not be larger 
than 15% for all the QCs. 
 
 
2.6.5 Stability 
 
For OME to guarantee the storage conditions and each step taken during sample 
preparation and analysis, the authors conducted the following stability assays at 4.5 
ng/mL (QCLow) and 1600 ng/mL (QCHigh): 
- after 3 cycles of freeze-thaw in the freezer at –80ºC 
- after 24 h at room temperature (short-term stability) 
- after 7 h at 23°C in the autosampler 
- after 72 h at 4ºC in the fridge 
- after 2 months at –80ºC in the freezer (long-term stability) 
14 
For all studies, 3 replicates of QCLow and QCHigh for OME were performed and analyzed 
according to requirements. Analyte stability had to be less than 15% for all the QCs 
used. 
 
 
2.2.7 Carry-over 
 
During validation, carry-over was assessed by injecting blank samples after a high 
concentration sample or CAL at the upper limit of quantification (2000 ng/mL). Carry-
over in the blank sample following the high concentration standard could not be greater 
than 20% of the LLOQ. The needle was washed between injections with water (55%) 
and ACN solution (45%) to prevent carry-over. 
 
 
2.2.8 Preliminary human experiments 
 
The proposed method was applied to determine the plasma profile of OME after a 
standard oral dose (40 mg single dose) of OME (Losec
®
, AstraZeneca) from 6 healthy 
volunteers under fasting conditions. Blood samples were taken at the following time 
intervals after dosing: 0, 0.66, 1, 1.33, 1.66, 2, 2.33, 2.66, 3, 3.33, 3.66, 4, 4.5, 5, 5.5, 6, 
7, 8, 10, and 12 h. Blood samples were collected in ethylenediaminetetra-acetic acid 
dipotassium dihydrate (EDTA K2) tubes (Vacuette
®
) and centrifuged at 3000 rpm for 10 
min at 4ºC. The plasma was separated and stored at –20ºC. The study was approved by 
the local ethics committee (Clinical Research Ethics Committee of “Hospital 
Universitario de la Princesa”, Madrid, Spain), and informed consent was obtained from 
15 
healthy volunteers. The pharmacokinetic analysis was carried out by means of a model-
independent method with WinNonLin Professional Edition, version 2.0 (Scientific 
Consulting, Inc, Cary, USA). Maximum plasma concentration (Cmax) and time of 
occurrence (Tmax) were determined directly from plasma concentration data. The area 
under the plasma concentration-time curve from time zero to the time of the last 
measurable concentration (AUC0-t) was calculated using the trapezoidal method. The 
AUC0-∞ was calculated as AUC0-t + Ct/k ratio, with Ct as the last detectable 
concentration and k the slope of the line obtained by linear regression from the points 
corresponding to the elimination phase. The half-life (T1/2) was calculated as ln2/k. 
 
 
3. Results 
 
3.1. Optimization of MS/MS conditions and chromatography 
 
The ESI in positive mode and full scan spectra of all compounds indicated that 
the most abundant ions were the protonated molecules ([MH]
+
), which were therefore 
selected to detect the most abundant products. The percent abundance of the precursor 
and product ions of the quantifier, qualifier, or IS versus mass to charge (m/z) are 
shown in Fig. 1A-B under product ion mode. The fragmentation patterns are also 
shown. Optimized mass spectrometer parameters such as scan time, fragmentor voltage, 
and collision energy for OME (quantifier and qualifier ion) and for its IS in MRM mode 
are summarized in Supplementary Table 1.  
Fig. 1C shows a typical extraction ion chromatogram (EIC) of plasma spiked 
with QCMedium (900 ng/mL) and its IS (1190 ng/mL) in MRM mode. The areas and 
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retention times (RT) are shown. Although the RT of OME (0.889 min) and its IS (0.884 
min) are very close, they can be separated by the analysis of EIC based on reconstructed 
ion currents. In addition, total recording time was too short (1.2 min) and did not require 
a post-time for re-equilibration owing to isocratic elution. 
 
 
3.2. Calibration curve and LLOQ 
 
The calibration curves with the 8 CALs of OME were linear in the range from 1.5 
ng/mL to 2000 ng/mL, with lines of regression forced through the origin. The slope and 
correlation coefficient (r
2
) values were 0.1152 ± 0.0039 and 0.9967 ± 0.0014, 
respectively, for the average of 6 calibration curves.  
The LLOQ at 1.5 ng/mL (Fig. 2) showed an identifiable and reproducible response with 
an intra-day accuracy of 4.3% and CV of 2.7% and inter-day accuracy of 13.0% and CV 
of 8.7% (Table 2). The response was more than 5 times higher than that of any target 
plasma (364 ± 16.65 signal/blank signal). In all CALs, the accuracy did not exceed 
±15% of the theoretical value, including the LLOQ. 
 
Supplementary Fig. 1A shows a representative total ion chromatogram (TIC) of a 
blank plasma sample without IS. Supplementary Fig. 1B and 1C display a typical EIC 
of blank plasma with IS (zero plasma) and plasma spiked with 1.5 ng/mL (LLOQ) of 
OME, respectively. The area values of LLOQ of OME (523) are higher than those 
found for this compound in a human blank plasma sample, taking into account that all 
chromatograms were normalized to the largest peak. 
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3.3. Precision and accuracy 
 
The precision and accuracy of the method were assessed by analyzing replicates of 5 
samples of 1.5 ng/mL (LLOQ), 4.5 ng/mL (QCLow), 900 ng/mL (QCMedium), and 1600 
ng/mL (QCHigh) for OME. The standard deviation (SD), CV, and accuracy were 
calculated for each sample. Table 1 summarizes the results for precision and accuracy 
of the validation method. The intra-day precision was optimal, with CVs of between 1% 
and 6%, and accuracy was optimal between 4% and 8%. Variations in inter-day 
precision were less than 15%, even for the LLOQ (1.5 ng/mL), with CVs of between 
5% and 13% and accuracy of between 7% and 13%. We can conclude that the method is 
reproducible and accurate for OME. 
 
 
3.4. Selectivity 
 
The present method was selective, as no interference was found in the detection of 
OME in the absence or presence of IS in 6 different blank samples. Supplementary 
Fig. 1 shows the lack of interference of a representative total ion chromatogram (TIC) 
of blank plasma samples with IS (Supplementary Fig. 1A) or without IS 
(Supplementary Fig. 1B). The area of the zero plasma with IS is much more than 20 
times the area of the blank plasma of OME (209,901 ± 16,589). Similarly, the EIC 
showed no interference at the LLOQ of OME (Supplementary Fig. 1C). 
 
 
3.5. Extraction recovery and matrix effect 
18 
 
The extraction recovery of human plasma was determined at 4.5 ng/mL (QCLow), 900 
ng/mL (QCMedium), and 1600 ng/mL (QCHigh) of OME compared with the blank plasma 
samples spiked with a known concentration of OME after SPE and immediately before 
injection. The mean recoveries were 103.8%, 87.0%, and 85.9%, and the CVs were in 
the range of 3% to 12% at the 3 given concentrations, respectively. Therefore, the 
extraction recoveries were higher than 86% and the bias less than 12%; the extraction 
was accurate and reproducible, as the recommendations suggest (Table 2).  
The matrix effect was carried out at 4.5 ng/mL (QCLow) and 1600 ng/mL (QCHigh) in 6 
different human plasma samples. The mean matrix effect (relative extraction) was more 
than 94%, and the CVs were in the range of 6% to 8%. No matrix effect was observed 
after the tests were performed; consequently, the response of OME was not significantly 
reduced by ion suppression (Table 2). 
 
 
3.6. Stability 
 
The stability assays at 4.5 ng/mL (QCLow) and 1600 ng/mL (QCHigh) of OME are 
summarized in Table 2. Stability tests after 3 freeze-thaw cycles in the freezer at –80ºC 
showed no degradation, with a mean of more than 95% and CV in the range of 2% to 
4%. The short-term stability test after 24 h at room temperature revealed a mean of 
more than 99% and CV in the range of 4% to 5%. After 7 h at 23ºC in the autosampler, 
the stability test revealed a mean of more than 98% and CV in the range of 1% to 6%. 
The stability test after 72 h at 4ºC in the fridge also showed a mean of more than 98% 
and CV in the range of 1 to 2. Moreover, the extracts were stable after 2 months at –
19 
80ºC (long-term), with a mean of more than 93% and CV in the range of 3% to 8%. The 
CV was less than 9% in all cases, and the mean was close to 100%. 
 
 
3.7. Carry-over 
 
The carry-over in the blank sample following the high-concentration standard 
calibration was 7.2 ± 4.76% of the LLOQ, i.e., less than 20%. Thus, in line with EMA 
regulations, OME did not present carry-over 
31
.  
 
 
3.8. Application of the method 
 
The method the authors developed was successfully applied to pharmacokinetic analysis 
of 240 samples from 6 healthy volunteers who received an oral dose of OME (Losec
®
,
 
40 mg). Fig. 2 shows OME plasma concentration versus time acquired after 
administration of OME (0 h to 12 h) in the 6 healthy volunteers. The average maximum 
plasma concentration (Cmax) was 1,395.18 ± 814.67 ng/mL at 1.61 (1.00-3.00) h (Tmax) 
after administration of OME. Table 3 shows the mean pharmacokinetic parameters of 
OME after oral administration of 40 mg of OME under fasting conditions. All the 
results were within the range of 1.5-2000 ng/mL in the calibration curves. “Our 
approach was similar to that of clinical practice, since 3 of the 6 healthy volunteers 
were taking concomitant therapy: norgestimate-ethinyl estradiol) 1 tablet/24 h, 
acetaminophen 1 g, and ibuprofen 600 mg. Even though these very common over-
20 
the-counter drugs were taken by our patients, the selectivity of our assay remained 
unaltered. No interference was observed with any of them during the study”. 
 
 
4. Discussion 
 
PPIs are among the most consumed over-the-counter drugs. OME is widely used and 
has marked inter-subject variability owing to the different activities of the cytochrome 
P450 system 
1, 22, 33
. Drug monitoring should take account of broad pharmacokinetic 
variability, which makes the relationship between dose and plasma concentration and 
therapeutic effect unpredictable. Administration of OME can become problematic 
because of drug-drug interactions, which are especially relevant in patients with chronic 
diseases and those taking multiple drugs concomitantly or drugs with a narrow 
therapeutic index 
2, 5
. Therefore, we developed an LC-MS/MS–based analytical method 
with SPE and isotope-labelled IS (OME-D3) to determine OME in human plasma, 
unravel new drug-drug interactions for pharmacokinetic studies, and thus improve 
clinical practice. 
 
“The method was linear within a wide range of concentrations (1.5 to 2000 ng/mL), 
which facilitated measurement of the high inter-subject variability between 
samples”. The LC-MS/MS the authors used had an LLOQ of 1.5 ng/mL for OME and 
higher sensitivity and selectivity than authors who used HPLC with UV detection 
between 3-96 ng/mL 
13-19
 . The most relevant LC-MS/MS–based methods have 
sensitivities of 0.05 ng/mL 
23, 24
, 0.4 ng/mL 
21
, and 1.2 ng/mL
22
, which were slightly 
lower than those used by the authors of the present study. In all of these studies, the run 
21 
times were longer, and samples were prepared using LLE or PPT. Even in SPE, which 
better eliminates the interference of the matrix effect, the run times were too long 
25, 29
. 
Dodgen and coworkers 
20
 recorded short run times, although they used automated online 
SPE, which is only available in selected laboratories and difficult to obtain for routine 
application in hospitals. 
 
Our chromatographic run lasted 1.2 min, which is shorter than times recorded elsewhere 
(>1.3 min 
13, 15, 17, 21-24
 or even >16 min 
17
). The authors used a Zorbax Extend C-18 
high-resolution column, which enabled us to work with a high flow of 0.8 mL min and 
provided a short analysis time.  
 
The mass spectrometer was operated with the ESI source, which can produce matrix 
effects that alter ionization efficiency owing to the presence of co-eluting substances 
such as phospholipids, mobile phase modifiers, and formulation agents 
34, 35
. “One of 
the advantages was the use of isotope-labeled IS and a more selective sample 
preparation procedure such as SPE, which helps to eliminate the matrix effect and 
improves assay selectivity 
28
, as in the present study”. The authors’ approach 
achieved good recoveries, with average values of 86% to 104%, which are similar to 
those reported by Dodgen and coworkers 
20
 and Macek and coworkers 
22
 or better than 
those reported elsewhere (>63% 
23
, 71% to 74% 
24
, and 83% to 87% 
17
). These 
recoveries were achieved thanks to an ultraclean polymeric sorbent of SPE, which has 
bimodal porosity and a high surface area. Both the mobile phase and the whole sample 
preparation procedure were conducted using basic solutions (pH 8.5) so as not to 
degrade OME, as reported elsewhere 
32
. The ratio of MeOH/ammonium acetate buffer 
at the washing step was critical to extraction yield, as reported by Martens-Lobenhoffer 
22 
and coworkers 
36
. The authors obtained the best result with 5% MeOH and 95% 
ammonium acetate, since a higher percentage of MeOH led to a loss of analyte. Other 
pH values (e.g., 9.5) during sample preparation, or decreasing percentages of 
ammonium acetate (e.g., 0.5 or 0.1) at the elution step did not increase the efficacy of 
recovery. “Another advantage of this procedure was that it did not require 
evaporation and subsequent reconstitution”. The authors also studied the effect of 
carry-over, which is not investigated by most authors, and recorded a value of 7.2%, 
which is lower than that allowed by the EMA 
31
, thus showing the quality of the method 
presented here. 
 
We also used small injection volumes (1 L) to minimize interference and matrix effect, 
since desorption is easier to perform. The method used only 200 L of plasma, which is 
less than that reported elsewhere (250 to 450 L 21-24 or even 1000 L 17). Hence, the 
quantity of plasma required to validate the bioanalytical methods is reduced. 
 
Finally, this procedure was successfully applied in the analysis of 240 samples from 6 
healthy volunteers with a mean (± SD) Cmax of 1395.18 ± 814.67 ng/mL. The mean 
plasma concentration was higher under fasting conditions than with food 
37
. These 
results are in line with those of previous reports on the pharmacokinetics of OME by 
Liu and coworkers (Cmax of 1330.46 ± 758.07 ng/mL) 
38
. Other authors reported lower 
Cmax owing to lower doses of OME 
24, 39
. The high inter-subject variability indicated by 
the error bars in Fig 2 is similar to the findings reported by other authors 
22, 38
, thus 
making them suitable for monitoring.  
 
5. Conclusion 
23 
 
“The advantages of the method presented here over other methods are as follows: 
1) the technique is linear in the range of 1.5 to 2000 ng/mL and does not require a 
dilution factor in most cases; 2) shorter run times (1.2 min); 3) good 
reproducibility, selectivity, recovery efficiencies (86% to 104%) and minimum 
matrix effect thanks to SPE, isotope-labelled IS, and a 1-L injection volume; 4) 
small plasma volume needed (200 L); 5) no carry-over effect; 6) no evaporation 
and reconstitution, since direct injection simplifies sample preparation. In 
summary, the LC-MS/MS method is consistent with the recommendations of the 
FDA 
30
 and EMA 
31
. It enables fast quantification of OME levels and is easily 
adapted to pharmacokinetic and drug-drug interaction studies”. 
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Figure Legends 
 
Fig. 1: Product ion mass spectra and chemical structure of [M+H]
+
 for omeprazole 
(OME, A) and its internal standard (IS), OME-D3 (B). The fragmentation pattern of 
OME and its IS are indicated by an arrow on the chemical structure of each compound. 
The precursor ion and the product ions are shown in the figure. The typical extraction 
ion chromatogram (EIC) of plasma spiked with 900 ng/mL (QCMedium) of OME and its 
IS under multiple reaction monitoring (MRM) mode. Retention times (RT) and height 
and area values are given for OME and OME-D3. These values were calculated from 
the EIC. All chromatograms have been normalized to the largest peak. 
 
Fig. 2: Mean plasma concentration of omeprazole (OME) versus time (A)  
 
Table 1. Intra-day and inter-day precision and accuracy. Data were obtained from 4 
quality controls (QCs) of omeprazole (OME; 1.5, 4.50, 900, and 1600 ng/mL) repeated 
5 times on the same day for precision and accuracy intra-day and on 3 consecutive days 
for inter-day assays. The lower limit of quantification (LLOQ) was 1.5 ng/mL. The 
mean ± SD of the number of total experiments is shown in parenthesis. 
 
Table 2. Extraction recoveries, matrix effect, and stability tests. Averaged data for 
extraction recoveries are the mean ± SD of 3 different blank human plasma samples 
spiked with 3 quality controls (QCs) of omeprazole (OME; 4.5, 900, and 1600 ng/mL) 
after solid phase extraction (SPE) and compared to 6 blank plasma samples under SPE 
and spiked with the same known concentrations of 3 QCs immediately before injection 
31 
in high-performance liquid chromatography (HPLC). Data are presented as a 
percentage of recovery. Average data for the matrix effect are the mean ± SD of 6 
different blank human plasma samples spiked with 2 QCs of OME (4.5 and 1600 
ng/mL) after SPE and compared to QCs without SPE. Data are presented as a 
percentage of recovery. The number of the total experiments is shown in parenthesis 
with each QC. The storage stability of OME (4.5 and 1600 mg/mL) in the human 
plasma sample after 3 freeze–thaw cycles (−80°C for 24 h at room temperature, 7 h at 
23°C in the autosampler, 72 h at 4ºC in the fridge, and 2 months at –80ºC in the 
freezer). Data are presented as a percentage of mean ± SD. The total number of 
experiments is shown in parenthesis with each QC.  
 
Table 3. Main pharmacokinetic parameters obtained after oral administration of 
omeprazole (OME 40 mg, Losec
®
) to 6 healthy volunteers. The pharmacokinetic 
parameters were maximum plasma concentration (Cmax), time to Cmax (Tmax), area under 
the plasma concentration-time curve (AUC0-t and AUC0-∞), and half-life (T1/2). All 
pharmacokinetic parameters were expressed as mean ± SD except Tmax, which is 
expressed as median with minimum and maximum values. 
 
Supplementary Fig. 1: Representative total ion chromatograms (TIC) of a blank 
human plasma sample without internal standard (IS) (A) and extraction ion 
chromatogram (EIC) of blank human plasma with IS (zero plasma, B). EIC of plasma 
spiked with the lower limit of quantification (LLOQ) at 1.5 ng/mL of omeprazole 
(OME, C). Retention times (RT) and height and area values are given for OME and IS. 
All chromatograms have been normalized to the largest peak. 
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Supplementary Table 1. Ions and fragmentation conditions used for multiple reaction 
monitoring (MRM) for omeprazole (OME) and its internal standard (IS), OME-D3.  
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Table 1.  
Mean ± SD 
 (ng/mL) 
CV  
(%) 
Accuracy  
(%) 
1.5 (LLOQ) 
4.5 
900 
1600 
Concentration 
(ng/mL) 
 Intra-day run 
 (n = 5) 956.39  16.36 
1733.12  11.43 
2.70 
5.87 
1.71 
0.66 
4.32 
3.75 
6.27 
8.32 
1.70  0.15 
5.16  0.67 
965.05  56.41 
1777.87  83.30 
8.70 
12.89 
5.84 
4.69 
13.01 
14.67 
7.23 
11.12 
Inter-day run 
(n = 15) 
1.56  0.04 
4.67  0.27 
1.5 (LLOQ) 
4.5 
900 
1600 
Table 1
Table. 2 
1600 85.94  10.14 11.80 
Extraction recovery 
(n = 3) 
Mean  SD  
 (%) 
Concentration 
(ng/mL) 
4.5 
900 
103.82  3.45 
87.01  8.92 
3.32 
10.25 
CV  
(%) 
4.5 
1600 
94.54  7.73 
100.74  6.26 
8.17 
6.21 
Matrix effect  
(relative extraction) 
(n = 6) 
4.5 
1600 
95.27  4.09 
103.99  2.17 
4.29 
2.09 
Freeze-thaw  
(3nd cycle)  
(n = 3) 
 Short-term  
for 24 h  
(n = 3) 
 
4.5 
1600 
99.66  4.48 
103.98  4.89 
4.50 
4.70 
Autosampler  
after 7 h at 23ºC 
(n = 3) 
 
4.5 
1600 
98.97  5.57 
100.45  0.76 
5.62 
0.76 
Fridge  
after 72 h at 4ºC 
(n = 3) 
  
4.5 
1600 
98.68  1.93 
99.34  1.36 
1.95 
1.37 
Long-term  
2 months at 80ºC 
(n = 3) 
  
4.5 
1600 
118.56  9.81 
93.48  3.13 
8.28 
3.35 
Table 2
Parameter OME (Losec®) 
Cmax (ng/mL) 1395.18 ± 814.67 
1.61 (1.00-3.00) 
0.84 ± 0.44 
Tmax (h) 
T1/2 (h) 
2312.44 ± 2783.21 
2322.88 ± 2800.39 
AUC0-t (ng x h/mL) 
AUC0-∞ (ng x h/mL) 
Table. 3 
Pharmacokinetic parameters of OME (mean ± SD) 
Table 3
